At 12.3% CAGR, the Europe Molecular Diagnostics for Infectious Disease Market is Projected to be Worth US$ 5,948.40 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the Europe molecular diagnostics for infectious disease market was valued at US$ 2,346.42 million in 2022 and is expected to reach US$ 5,948.40 million by 2030, registering a CAGR of 12.3% from 2022 to 2030. Advancements in molecular diagnostics technologies and surging prevalence of infectious disease globally are among the critical factors attributed to the Europe molecular diagnostics for infectious disease market expansion.

Genetic and genomic research has led to the development of molecular diagnostic techniques that focus on nucleic acid detection, which provide new methods for detecting infectious diseases with a fast turnaround time. A molecular diagnostic technique detects multiple pathogens and analyzes drug-resistant genes of pathogens and pathogen homology analysis, making it an increasingly important tool for the early diagnosis of infectious diseases. Molecular diagnostic techniques and platforms are used in all areas of anatomic and clinical pathologies. DNA or RNA sequences associated with disease, including single nucleotide polymorphism, deletions, rearrangements, and insertions, can be detected via molecular diagnostic tests. Conventionally, CT scans, hematological tests, and reverse transcription-PCR (RT-PCR) were used for testing. Due to growing infectious diseases, the need for rapid, precise testing platforms surged to overcome the disadvantages of conventional testing. Computed tomography (CT), a cost-intensive procedure that may not be available in all hospitals, fails to detect viral infections and other diseases in asymptomatic patients. RT-PCR was also time-consuming and could not detect a low viral load during the early stages of infection. Reverse transcription loop-mediated isothermal amplification (RT-LAMP), microarray-based detection, aptamer-based diagnosis, SHERLOCK, SHERLOCKv2, FET Biosensors, cell-based potentiometric diagnosis, and molecular imprinting technology are a few examples of novel molecular diagnostics techniques developed for infectious disease diagnosis. In the last few years, the FDA reports have indicated that molecular testing, antigen-dependent testing, and serological testing have been approved due to the advancements. Collaborative efforts by scientific communities in different countries to manage infectious diseases and reduce the extent of mortality have benefited the overall molecular tools and diagnosis landscape, which will likely create significant opportunities for the molecular diagnostics for infectious diseases market in the future.

On the contrary, limitations associated with molecular testing hampers the growth Europe molecular diagnostics for infectious disease market.

Based on type, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held 62.2% share of Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 1,459.00 million. It is projected to garner US$ 3,622.00 million by 2030 to expand at 12.0% CAGR during 2022-2030.

The Europe molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held 94.7% share of the Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 840.04 million. It is projected to garner US$ 2,191.08 million by 2030 to expand at 12.7% CAGR during 2022-2030. Additionally, the human testing segment, by laboratory testing, held 94.5% share of the Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 1,378.50 million. It is projected to garner US$ 3,404.64 million by 2030 to expand at 12.0% CAGR during 2022-2030.

Based on application, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held 46.6% share of the Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 413.64 million. It is projected to garner US$ 1,063.65 million by 2030 to expand at 12.5% CAGR during 2022-2030. Additionally, the drug regimen selection segment, by laboratory testing, held 36.8% share of the Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 536.38 million. It is projected to garner US$ 1,326.02 million by 2030 to expand at 12.0% CAGR during 2022-2030.

Based on disease type, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held 63.6% share of the Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 564.65 million. It is projected to garner US$ 1,506.61 million by 2030 to expand at 13.1% CAGR during 2022-2030. Additionally, the STDs segment, by laboratory testing, held 52.2% share of the Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 760.99 million. It is projected to garner US$ 1,928.05 million by 2030 to expand at 12.3% CAGR during 2022-2030.

Based on infection type, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held 49.0% share of the Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 434.78 million. It is projected to garner US$ 1,119.95 million by 2030 to expand at 12.6% CAGR during 2022-2030. Additionally, the bacteria segment, by laboratory testing, held 48.7% share of the Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 710.52 million. It is projected to garner US$ 1,733.35 million by 2030 to expand at 11.8% CAGR during 2022-2030.

Based on country, the Europe molecular diagnostics for infectious disease market is categorized into the UK, Germany, France, Italy, Spain, Austria, Belgium, Luxembourg, the Netherlands, and the Rest of Europe. Germany held 29.3% share of Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 687.27 million. It is projected to garner US$ 1,699.46 million by 2030 to expand at 12.0% CAGR during 2022-2030.

Key players operating in the Europe molecular diagnostics for infectious disease market are Abbott Laboratories, bioMerieux SA, Bruker Corp, Danaher Corp, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc, Molzym GmbH & Co KG, Siemens Healthineers AG, and Thermo Fisher Scientific Inc, among others.

• In Dec 2021, Roche launched the first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark. The launch of the cobas omni Utility Channel enables laboratory professionals the flexibility of running CE-IVD assays, as well as designing their own laboratory developed tests (LDTs). This new offering expands access to critical and robust diagnostic tools that enables healthcare providers to deliver high quality care to patients worldwide, including access to regions with the highest disease burdens.
  
  
  
  
  Contact Us
  Phone: +16467917070
  Email Id: sales@businessmarketinsights.com